David Westenberg
Stock Analyst at Piper Sandler
(4.23)
# 425
Out of 4,944 analysts
172
Total ratings
53.68%
Success rate
14.16%
Average return
Main Sectors:
Stocks Rated by David Westenberg
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| PACB Pacific Biosciences of California | Maintains: Neutral | $1.25 → $1.5 | $1.21 | +23.97% | 9 | Aug 11, 2025 | |
| ZTS Zoetis | Maintains: Overweight | $210 → $215 | $149.77 | +43.55% | 15 | Aug 11, 2025 | |
| IDXX IDEXX Laboratories | Maintains: Neutral | $510 → $700 | $652.27 | +7.32% | 11 | Aug 11, 2025 | |
| ELAN Elanco Animal Health | Maintains: Neutral | $12 → $18 | $17.43 | +3.27% | 10 | Aug 11, 2025 | |
| NTRA Natera | Maintains: Overweight | $210 → $220 | $159.81 | +37.66% | 16 | Aug 11, 2025 | |
| EXAS Exact Sciences | Maintains: Overweight | $70 → $60 | $41.74 | +43.75% | 11 | Aug 11, 2025 | |
| ADPT Adaptive Biotechnologies | Maintains: Overweight | $13 → $15 | $12.66 | +18.48% | 14 | Aug 6, 2025 | |
| NEO NeoGenomics | Maintains: Overweight | $12 → $11 | $6.08 | +80.92% | 10 | Aug 4, 2025 | |
| WGS GeneDx Holdings | Maintains: Overweight | $110 → $120 | $116.41 | +3.08% | 2 | Aug 4, 2025 | |
| FLGT Fulgent Genetics | Maintains: Neutral | $23 → $21 | $21.01 | -0.05% | 9 | Aug 4, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $55 → $70 | $66.34 | +5.52% | 4 | May 15, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $190 → $185 | $97.38 | +89.98% | 16 | May 15, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $260 → $280 | $269.31 | +3.97% | 4 | May 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $50 → $60 | $55.10 | +8.89% | 9 | May 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $180 → $200 | $178.68 | +11.93% | 7 | Apr 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $6.4 → $5 | $5.23 | -4.40% | 12 | Apr 22, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $8.5 → $8 | $4.03 | +98.51% | 9 | Mar 4, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | n/a | $12.81 | - | 1 | Mar 5, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | n/a | $25.19 | - | 2 | Jan 4, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | n/a | $50.65 | - | 1 | Nov 21, 2017 |
Pacific Biosciences of California
Aug 11, 2025
Maintains: Neutral
Price Target: $1.25 → $1.5
Current: $1.21
Upside: +23.97%
Zoetis
Aug 11, 2025
Maintains: Overweight
Price Target: $210 → $215
Current: $149.77
Upside: +43.55%
IDEXX Laboratories
Aug 11, 2025
Maintains: Neutral
Price Target: $510 → $700
Current: $652.27
Upside: +7.32%
Elanco Animal Health
Aug 11, 2025
Maintains: Neutral
Price Target: $12 → $18
Current: $17.43
Upside: +3.27%
Natera
Aug 11, 2025
Maintains: Overweight
Price Target: $210 → $220
Current: $159.81
Upside: +37.66%
Exact Sciences
Aug 11, 2025
Maintains: Overweight
Price Target: $70 → $60
Current: $41.74
Upside: +43.75%
Adaptive Biotechnologies
Aug 6, 2025
Maintains: Overweight
Price Target: $13 → $15
Current: $12.66
Upside: +18.48%
NeoGenomics
Aug 4, 2025
Maintains: Overweight
Price Target: $12 → $11
Current: $6.08
Upside: +80.92%
GeneDx Holdings
Aug 4, 2025
Maintains: Overweight
Price Target: $110 → $120
Current: $116.41
Upside: +3.08%
Fulgent Genetics
Aug 4, 2025
Maintains: Neutral
Price Target: $23 → $21
Current: $21.01
Upside: -0.05%
May 15, 2025
Maintains: Neutral
Price Target: $55 → $70
Current: $66.34
Upside: +5.52%
May 15, 2025
Maintains: Overweight
Price Target: $190 → $185
Current: $97.38
Upside: +89.98%
May 6, 2025
Maintains: Neutral
Price Target: $260 → $280
Current: $269.31
Upside: +3.97%
May 6, 2025
Maintains: Overweight
Price Target: $50 → $60
Current: $55.10
Upside: +8.89%
Apr 28, 2025
Maintains: Neutral
Price Target: $180 → $200
Current: $178.68
Upside: +11.93%
Apr 22, 2025
Maintains: Neutral
Price Target: $6.4 → $5
Current: $5.23
Upside: -4.40%
Mar 4, 2025
Maintains: Overweight
Price Target: $8.5 → $8
Current: $4.03
Upside: +98.51%
Mar 5, 2020
Initiates: Buy
Price Target: n/a
Current: $12.81
Upside: -
Jan 4, 2018
Upgrades: Buy
Price Target: n/a
Current: $25.19
Upside: -
Nov 21, 2017
Initiates: Neutral
Price Target: n/a
Current: $50.65
Upside: -